Vitamin C and Zinc in Patients With Enterocutaneous Fistulas.
Effectiveness of Doses of Vitamin c and Zinc in Patients With High Enterocutaneous Fistulas Receiving Nutrition Parenteral Therapy on Closure and Recurrence. Randomized Clinical Trial.
Hospital Juarez de Mexico
76 participants
Aug 1, 2023
INTERVENTIONAL
Conditions
Summary
Various micronutrients play an important role in the process of closure and recurrence of enterocutaneous fistulas, such as Vitamin C and Zinc. However, there is no specific recommendation on the dose of these nutrients by parenteral route.
Eligibility
Inclusion Criteria4
- Women and men
- \>18 years and \<70 years old.
- Diagnosis of high-output enterocutaneous fistula for the first time
- Need for parenteral nutrition
Exclusion Criteria8
- Octreotide use
- Palliative care
- Steroid use
- Oxalate nephropathy
- G6PD deficiency
- Hemochromatosis
- Abdominal surgeries in the last 6 months
- Hospitalizations for more than 15 days in the last 6 months
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
This is a randomized, control trial to investigate the effect of Vitamin C and Zinc in patients with enterocutaneous fistulas receiving nutrition parenteral therapy and Vitamin C 100-300 mg/d and zinc 3-5 mg/d
This is a randomized, control trial to investigate the effect of Vitamin C and Zinc in patients with enterocutaneous fistulas receiving nutrition parenteral therapy and Vitamin C 1000-2000 mg/d y zinc 10-15 mg/d
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06009744